Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    Vivek Ramaswamy’s Plans

    I last wrote about Vivek Ramaswamy in the context of his first company (Axovant). That one went public on the hopes for a retread Alzheimer’s drug to work out in Phase III, and if that sounds a little iffy to you, then join a fairly large club. Alzheimer’s is truly the approach-avoidance conflict writ large: from… Read More
  • Alzheimer's Disease

    Simple, Right?

    So, name a class of prescription drugs that lots of people have been taking daily over a period of decades: how about statins? From a distance, the story is completely understandable: statins inhibit the enzyme HMG-CoA reductase, which shuts down a key step in cholesterol biosynthesis. That lowers the amount of cholesterol in the body… Read More
  • Alzheimer's Disease

    Clinical Trials, Up and Very Much Down

    Lots of news at both ends of the scale today. At the bad end would be Arrowhead Pharma, who have been exploring therapeutic RNA interference. That’s a hard row to hoe, and nothing illustrates that better than their announcement that they’re dropping three clinical programs, pretty much all the advanced research that they have, because… Read More
  • Academia (vs. Industry)

    Vanderbilt Heads Into the Clinic for Alzheimer’s

    There’s an interesting experiment underway at Vanderbilt, where a team from the university is taking a possible Alzheimer’s candidate into clinical trials on their own. Now, you could come up with several headlines for this, along the lines of “Academic researchers in way over their heads”, or “Plucky professors make e… Read More
  • Alzheimer's Disease

    Eli Lilly’s Alzheimer’s Antibody Does Not Work

    After years of work and untold amounts of money, Eli Lilly’s Alzheimer’s antibody, solanezumab, does not work. It does not help Alzheimer’s patients. No matter how many times you run the Phase III trials, or in which patient populations, they do not get better. No matter how many hopeful press articles you might have seen… Read More
  • Alzheimer's Disease

    A New Way to Make GSK3 Inhibitors

    Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I started reading the literature, I quickly felt as if I were late to the party. It’s been investigated for diabetes (and other metabolic diseases), Alzheimer’s… Read More
  • Alzheimer's Disease

    The Best Beta-Secretase Inhibitor Yet in Alzheimer’s

    Merck has published new results on their latest Alzheimer’s drug candidate, the beta-secretase inhibitor verubecestat (MK-8931). The paper in Science Translational Medicine is quite interesting, both for what it says and what it doesn’t (or can’t, yet). BACE inhibitors have had quite a time of it over the years. Coming up with a m… Read More
  • Alzheimer's Disease

    The Limits of Big Data

    I fear that mentioning the phrase “Big Data” in the first sentence of a blog post will make half the potential readers suddenly remember that they have podiatrist appointments or something. But that’s the only way to approach this article at Wired. After all, the title is “The Cure For Cancer is Data – Mountains of… Read More
  • Alzheimer's Disease

    Bill Gates and His Moonshot

    The rocket’s supposed to be moving, and it probably is, but everyone knows that you can’t see that with the naked eye. Not at first. The announcer said “Lift-off” – well, that probably happened sometime during the lunch hour, it’s easy to miss – and the first thing you look for is the exhaust starting… Read More
  • Alzheimer's Disease

    Just How Worthless Are the Standard Alzheimer’s Models?

    As mentioned yesterday, Alzheimer’s therapies have, for the most part, been a cliff over which people push bales of money. There are plenty of good reasons for this: we don’t really know what the cause of Alzheimer’s is, when you get down to it, and we’re the only animal that we know of that gets… Read More
123...